Daiichi Sankyo And AstraZeneca Launch Three Phase 3 Trials For Datopotamab Deruxtecan-Based Combinations In Advanced Nonsquamous NSCLC; TROPION-Lung10, Lung14, And Lung15 Studies Target High PD-L1 Expression And EGFR Mutations With First Patients Dosed
Daiichi Sankyo And AstraZeneca Launch Three Phase 3 Trials For Datopotamab Deruxtecan-Based Combinations In Advanced Nonsquamous NSCLC; TROPION-Lung10, Lung14, And Lung15 Studies Target High PD-L1 Expression And EGFR Mutations With First Patients Dosed
第一三共和阿斯利康共同展开三项第三期试验,针对爱文思控股基因药datopotamab deruxtecan联合用于晚期非鳞状NSCLC;TROPION-Lung10、Lung14和Lung15研究以高PD-L1表达和EGFR突变为目标,首批患者已接受投药。
Daiichi Sankyo And AstraZeneca Launch Three Phase 3 Trials For Datopotamab Deruxtecan-Based Combinations In Advanced Nonsquamous NSCLC; TROPION-Lung10, Lung14, And Lung15 Studies Target High PD-L1 Expression And EGFR Mutations With First Patients Dosed
第一三共与阿斯利康启动了三项III期试验,针对爱文思控股基础组合治疗的晚期非鳞状细胞非小细胞肺癌;TROPION-Lung10、Lung14和Lung15研究以高PD-L1表达和EGFR突变作为目标,首批患者已接受投药。